The investment includes a $50m secondary share purchase from Info Edge and values restaurant listings platform Zomato at $1.1bn.

Personal travel assistant developer Mezi had raised $9m in an American Express Ventures-backed series A round 18 months ago.

The respiratory tract infection therapy developer, which counts Novartis and PureTech Health as investors, has closed its IPO at $97.8m.

Infrastructure automation technology developer CoreOS, which had raised $48m from investors including GV and Intel Capital, has agreed to an acquistion by Red Hat.

The pruritus treatment developer, which counts Novo and Merck & Co as shareholders, has closed its initial public offering, its shares having almost doubled in price.

The immuno-oncology drug developer, which is backed by Celgene and GV, floated above its range and has since seen its share price rise 75%.

The seed and fertliliser producer, which counts Monsanto as an investor, has set the range for an initial public offering that could net up to $142m.

Skyport Systems had raised $67m in funding from investors including Cisco Investments and was valued at $245m as of 2016.

Michigan’s Armune Bioscience has been bought by Exact Science, which plans to expand its cancer diagnostics range with Armune’s prostate cancer test.

The round will enable medical apparel producer Figs to buy out its earlier investors, which include Crocs, leaving Tulco its only external backer.